Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

September 01, 1999; 53 (5) Articles

Nutritional status is a prognostic factor for survival in ALS patients

J.C. Desport, P.M. Preux, T.C. Truong, J.M. Vallat, D. Sautereau, P. Couratier
First published September 1, 1999, DOI: https://doi.org/10.1212/WNL.53.5.1059
J.C. Desport
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.M. Preux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T.C. Truong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.M. Vallat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Sautereau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Couratier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Nutritional status is a prognostic factor for survival in ALS patients
J.C. Desport, P.M. Preux, T.C. Truong, J.M. Vallat, D. Sautereau, P. Couratier
Neurology Sep 1999, 53 (5) 1059; DOI: 10.1212/WNL.53.5.1059

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
896

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the occurrence of malnutrition in patients with ALS, to assess the relation of malnutrition to the neurologic deficit, and to determine the impact of nutritional status on patient survival.

Background: Although ALS may be associated with significant malnutrition, the relative impact on patient survival has not yet been well established.

Methods: In a prospective 7-month study of 55 ALS patients in a referral neurology practice, nutritional status was assessed by calculating body mass index. Neurologic evaluation includes four functional scores and identifies the form of disease onset. Slow vital capacity (VC) was also measured.

Results: Occurrence of malnutrition in patients studied was 16.4%. Survival (using the Kaplan–Meier method) was worse for malnourished patients (p < 0.0001), with a 7.7-fold increased risk of death. Using multivariate analysis, only reduced VC (p < 0.0001) and malnutrition (p < 0.01) were found to have significant independent prognostic value. The degree of malnutrition is independent of neurologic scores and of forms of ALS onset.

Conclusion: Nutritional surveillance of ALS patients is very important, both in bulbar-onset and spinal-onset patients.

ALS results from the progressive degeneration of the lower and upper motor neurons in the anterior horn of the spinal cord, brainstem, and cerebral cortex respectively. The prognosis is grave, and survival ranges from 18 to 40% 5 years after disease onset.1,2 Classically, clinical diagnosis distinguishes between forms with spinal onset (characterized by progressive amyotrophy of the extremities) and those with bulbar onset (marked by a labioglossopharyngeal paresis causing difficulty in speaking, chewing, and swallowing).1-4 In 10 to 30% of patients, the presenting sign of the disease is dysphagia, which will ultimately affect nearly all ALS patients over the course of the disease.5 Episodes of aspiration are also likely, leading to reduced alimentary intake.2,6

The goals of this study are to determine in ALS patients the occurrence of malnutrition, defined by a body mass index (BMI) ≤ 18.5 kg/m2, to evaluate the relation of malnutrition to the degree of neurologic deficit, and to evaluate the impact of nutritional status on the survival after the nutritional assessment of these patients.

Methods.

A total of 55 patients with definite or probable ALS according to the criteria of El Escorial7 seen in our referral neurology practice were enrolled in the study between March 15, 1996, and October 16, 1997. No patients were excluded or refused. The patients underwent an interventional assessment that consisted of coupled, detailed evaluations in the neurology and nutritional clinics. The protocol was approved by the regional ethics committee. During the neurologic evaluation, the date of onset of the first disease symptoms (fasciculations; cramps; weakness; speaking, chewing, and swallowing disorders; etc.) was elucidated by neurologic history. The variable of interest was time since entry into the study.8,9 Patients were followed until death or until the closing date of the study (December 1, 1997). No patient was lost to follow-up. Neurologic deficit was quantified by manual muscle testing of the neck and upper and lower extremities as defined by the Medical Research Council10 (maximal value, 150 points), the modified Norris scales for limbs (maximal value, 63 points) and bulbar function11 (maximal value, 39 points), and the ALS Functional Rating Scale12 (ALS FRS; maximal value, 40 points). Slow respiratory vital capacity (VC) was measured using a Hans Rudolph pneumotachograph, integrated in a body plethysmography system (CPF Medical Graphics, St. Paul, MN). Results were expressed in relation to a theoretical calculated index value. All patients were treated with a benzothiazole (riluzole) with the goal of reducing neuronal excitotoxin-related disease progression,13 and the starting date of treatment was noted.

For the nutritional assessment, weight was recorded to the 0.1 kg with a scale (Seca, Vogel & Halke, Hamburg, Germany), and height was measured to 0.5 cm using a SECA height gauge. BMI was calculated according to the formula BMI = weight (kg)/height2 (m). BMI ≤ 18.5 kg/m2 defined malnutrition.14 A possible subsequent placement of gastrostomy for enteral feeding was noted.

Statistical analyses were conducted using Statview 4.5 F software (Abacus Concept, Inc., Berkeley, CA) and Epitable 2.0 (Centers for Disease Control and Prevention, Atlanta, GA, and Epicentre, Paris, France). Qualitative results were compared using Pearson’s chi-square test or Fisher’s exact test. Quantitative averages were compared using the Mann–Whitney U test. Survival was analyzed using the Kaplan–Meier method,9 and comparisons between malnourished and nonmalnourished patient groups were performed using a logrank test. Multivariate analysis was performed using a Cox regression model.15 The threshold of significance was set at 0.05 for all statistical analyses.

Results.

A total of 55 different patients were seen during the study period. Their principal characteristics, obtained during the interventional (first) study visit, are presented in table 1. Time between initial signs and interventional assessment was 29 ± 25 months (average ± SD). The cumulative 75% survival (25% mortality) was reached by the 26th month from initial signs. The mean follow-up period was 7 ± 4 months. A total of 32% of patients died during the study period (bulbar, 41.7%; spinal, 25.8%).

View this table:
  • View inline
  • View popup
Table 1.

Principal patient characteristics of the whole population and as a function of nutritional status as defined by BMI obtained during the interventional (first) study visit

Neurologic and respiratory evolution results were as follows: survival was worse for bulbar ALS patients (mean bulbar, 30 months; spinal, 37 months; p = 0.05), and this form had age at onset older than the spinal form (63 years versus 58 years; p = 0.05). Higher age at onset showed a trend for reduced survival (age > 60 years, 31 months; age < 60 years, 37 months; p = 0.06). Survival was greater for patients with VC > 60% (8.5 months) than those with VC reduced below this level (3.8 months; p < 0.0001; figure 1). Survival duration was independent of the intensity of motor deficit for all the scoring scales used.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Kaplan–Meier survival plot of patients according to slow respiratory vital capacity (VC). The difference between the patients with VC ≥ 60% (thick line) and the patients with VC < 60% (thin line) is highly significant (p < 0.0001).

Malnutrition was diagnosed in 16.4% of patients. The main characteristics of malnourished or nonmalnourished patients are compared in table 1.

Survival duration was shorter in malnourished than nonmalnourished patients (p < 0.0001), and nutritional status was a fundamental predictive factor for survival (figure 2). Two alternative methods of nutritional assessment were used, and they agreed with the BMI results (unpublished observations). Univariate relative risk of death was increased 7.7-fold (95% CI, 3.0 to 20.2) for patients with malnutrition.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Kaplan–Meier survival plot of patients in the nonmalnourished (NM; thick line) and malnourished (M; thin line) groups according to nutritional status as determined by body mass index. The difference between malnourished and nonmalnourished patients is highly significant (p < 0.0001).

On average, the VC percentage was lower in the malnourished group. The difference between the two groups, however, did not reach statistical significance (see table 1), suggesting that nutritional status and VC were not correlated. Among the malnourished patients, there were no more bulbar than spinal ALS patients (bulbar, 8 of 9; spinal, 8 of 9).

Lastly, a multivariate analysis determined only two significant, independent prognostic factors after adjusting for ALS type, disease duration prior to consultation, duration of riluzole treatment, age at onset, and presence of a gastrostomy. These factors were VC and malnutrition as assessed by BMI. In this model, patients with VC < 60% multiplied the risk of death by 22.0 (95% CI, 5.0 to 97.1; p < 0.0001), and being malnourished multiplied the risk of death by 7.4 (95% CI, 1.7 to 32.1; p < 0.01).

At the time of the interventional consultation, 3 patients already had a feeding gastrostomy in place, and 16 patients had a feeding gastrostomy placed during the study period, with placement determined by a loss of 5 to 10% of former body weight. Gastrostomy placement occurred an average of 71 ± 117 days after the interventional examination date. None of these results was modified if one excludes the patients who had enteral nutritional support during the study period.

Discussion.

Comparison between patient populations in the current study with other published reports is problematic, because the only five prior studies analyzing the nutritional status of patients with ALS have small study populations with heterogeneous patient characteristics2,6,16-18 (table 2). The mean BMI of patients in our study is normal (23 ± 5 kg/m2), similar to the values reported elsewhere (18 to 30 kg/m2), although this index measure is only given in two of five studies.2,16 The percent of bulbar and spinal ALS types are provided in only one study,16 in which bulbar type initial presentation is only 14% of studied patients, and there is no explanation for this low number. The comparable percent we report—43.6%—is slightly higher or similar to the ratio with bulbar onset reported elsewhere in the published literature.4,19-21 The time between initial signs and interventional assessment in our patients (29 ± 25 months) is similar to that reported by different authors.2,16,17 Just one study16 addresses the percent of study patients having a gastrostomy (45%), which is slightly higher than in our patient population (34%). Additionally, our patients have similar age characteristics compared with those reported in two earlier studies conducted in our hospital, and compared with those reported classically for ALS populations.4,21-23

View this table:
  • View inline
  • View popup
Table 2.

Principal patient characteristics and techniques used in cited ALS studies with a nutritional focus

Using our criteria of malnutrition with BMI, 16.4% of our patients are malnourished. BMI is often taken into consideration2,16 with different threshold levels. We have chosen those proposed by Torun and Chew14 according to James et al.24 Concerning the occurrence of malnutrition in ALS patients, the compared criteria are quite disparate in the literature. It has already been reported that alimentary intake of patients is balanced with energy expenditure at the onset of their medical care, and subsequently that intake drops below their requirements if no nutritional intervention is made.17 By contrast, Mazzini et al.16 report that at the onset of medical attendance, 53% of their patients had a BMI < 20 kg/m2, and 55% had a weight loss > 15% of their usual weight, indicating a high occurrence of malnutrition. A study published in 1983 found weight loss of 10% or greater in 24% of patients, insufficient alimentation (or food intake) in 70% of patients, and, based on anthropometric criteria, a high occurrence of malnutrition; however, these criteria have since been rejected for having too low a threshold.6 According to Kasarskis et al.,2,25 inadequate oral intake relative to energy consumption is observed in acccordance with disease progression, and in parallel with a drop in BMI. Therefore, although malnutrition is reported as being frequent in studied ALS populations, agreement regarding its occurrence is lacking. Yet it seems reasonable to accept an occurrence that ranges from 15 to 55% if one combines patients at all stages of the disease.

For the population studied, the existence of a state of malnutrition is a clearly negative prognostic factor for survival. It has already been suggested in the study by Mazzini et al.,16 in which an improvement in patients’ nutritional status via enteral feeding by gastrostomy, quantified by an improvement in BMI, yielded improved survival by 6 months follow-up. They propose attentive surveillance of patients’ nutritional status, particularly if bulbar signs appear. They advocate prompt consideration of gastrostomy placement for enteral feeding according to the recommendations of Leigh and Ray–Chaudhuri,20 and set the tolerable limit for total weight loss at 10%. Kasarskis et al. (personal communication cited in Kasarskis et al.2) cite the strong correlation between reduced BMI and shortened survival, and insist on the importance of providing nutritional supplementation to all patients with ALS as their alimentary intake falls below their requirements well before the terminal phase of the disease.2,25 They recommend enteral feeding when the weight loss relative to usual weight reaches 5% or when clear bulbar dysfunction develops.25 Nevertheless, neither of these studies document how the threshold of 5% or 10% weight loss is chosen.

Factors influencing survival significantly in our study are compared with literature data: ALS with bulbar type onset is a negative prognostic factor,1,21 as is reduction in VC.26 Higher age at disease onset is at threshold significance.

In our study, the three methods for evaluating neurologic deficit have no prognostic value. This may be due primarily to the short follow-up period. Moreover, muscle strength testing is a semiquantitative, insensitive method, and yields scores with nonuniform distribution.27 The Norris scales provide a good global disease assessment, but rely on subjective criteria,27 and although the ALSFRS addresses all functions that may be affected by ALS, our study does not confirm the hypothesized prognostic value of this method,28 perhaps because of its subjective nature.

Malnutrition causes rapid muscle wasting,29 yet the magnitude of neurologic deficits in our study are independent of nutritional status. This may be related to the fact that assessment of disease severity is determined globally, and thus takes into account indicators with equal or greater importance than nutritional state, but with a faster progression.

Although bulbar onset of ALS can be regarded as a much greater risk of malnutrition than spinal-onset disease, in our study occurrence of malnutrition does not differ between the two disease types. If inadequate caloric intake and weight loss correlate with severity of dysphagia in most ALS patients,1,3,4,25 it is possible that a higher energy expenditure due to spasticity and fasciculations occurs in some spinal-onset forms of ALS.

Acknowledgments

Acknowledgment

The authors are indebted to P. Bernard Beaufrère (Laboratoire de Nutrition Humaine, Clermont-Ferrand, France) for reviewing the manuscript and to Dr. Valérie Newman–Chalifour for translating it into English.

  • Received May 8, 1998.
  • Accepted April 24, 1999.

References

  1. ↵
    Lee JR-J, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207–215.
    OpenUrlCrossRefPubMed
  2. ↵
    Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 1996;63:130–137.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Depaul R, Abbs JH. Manifestations of ALS in the cranial motor nerves. Dynametric, neuropathologic, and speech motor data. Neurol Clin 1987;5:231–250.
    OpenUrlPubMed
  4. ↵
    Norris FH, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neurone disease. J Neurol Sci 1993;118:48–55.
    OpenUrlCrossRefPubMed
  5. ↵
    Robbins J. Swallowing in ALS and motor neurone disorders. Neurol Clin 1987;5:213–229.
    OpenUrlPubMed
  6. ↵
    Slowie LA, Paige MS, Antel JP. Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS). J Am Diet Assoc 1983;83:44–47.
    OpenUrlPubMed
  7. ↵
    Subcommittee on Motor Neurone Disease/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases, El Escorial Clinical Limits of Amyotrophic Lateral Sclerosis Workshop contributors.El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124 (suppl):96–107.
  8. ↵
    Andersen PK, Keiding N. Survival analysis, overview. In: Armitage P, Colton T, ed. Encyclopedia of biostatistics. Chichester, UK:Wiley, 1998:4452–4461.
  9. ↵
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
    OpenUrlCrossRef
  10. ↵
    Aid to the investigation of peripheral nerve injuries. In: Medical Research Council, ed. War memorandum, 2nd ed., revised. London: His Majesty’s Stationery Office, 1943:11–46.
  11. ↵
    Norris FH Jr. Charting the course in amyotrophic lateral sclerosis. In: Rose FC, ed. Amyotrophic lateral sclerosis. New York:Demos, 1990:83–92.
  12. ↵
    The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.The Amyotrophic Lateral Sclerosis Functional Rating Scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996;53:141–147.
    OpenUrlCrossRefPubMed
  13. ↵
    Bensimon G, Lacomblez L, Meininger V, the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585–591.
    OpenUrlCrossRefPubMed
  14. ↵
    Torun B, Chew F. Protein–energy malnutrition. In: Shils ME, Olson JA, Shike M, eds. Modern nutrition in health and disease. 8th ed., vol. II. Philadelphia: Lea & Febiger, 1993:959–960.
  15. ↵
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187–220.
    OpenUrl
  16. ↵
    Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695–698.
    OpenUrlCrossRefPubMed
  17. ↵
    Nau KL, Bromberg MB, Forshew DA, Katch VL. Individuals with amyotrophic lateral sclerosis are in caloric balance despite losses in mass. J Neurol Sci 1995;129 (suppl):47–49.
  18. ↵
    Shimizu T, Hayashi H, Tanabe H. Energy metabolism of ALS patients under mechanical ventilation and tube feeding. Clin Neurol 1991;31:255–259.
    OpenUrl
  19. ↵
    Scarpa M, Colombo A, Panzetti P, Sorgato P. Epidemiology of amyotrophic lateral sclerosis in the province of Modena, Italy. Influence of environmental exposure to lead. Acta Neurol Scand 1988;77:456–460.
    OpenUrlPubMed
  20. ↵
    Leigh PN, Ray–Chaudhuri K. Motor neurone disease. J Neurol Neurosurg Psychiatry 1994;57:886–896.
    OpenUrlFREE Full Text
  21. ↵
    Preux PM, Couratier P, Boutros–Toni F, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology 1996;15:153–160.
    OpenUrlCrossRefPubMed
  22. Chazot F, Vallat JM, Hugon J, Lubeau M, Dumas M. Amyotrophic lateral sclerosis in Limousin. Neuroepidemiology 1986;5:39–46.
    OpenUrlCrossRefPubMed
  23. ↵
    Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival predication. Brain 1995;118:707–719.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    James WPT, Ferro–Luzzi A, Waterlow JC. Definition of chronic energy deficiency in adults. Eur J Clin Nutr 1988;42:969–981.
    OpenUrlPubMed
  25. ↵
    Kasarskis EJ, Neville HE. Management of ALS: nutritional care. Neurology 1996;47 (suppl 2):S118–S120.
  26. ↵
    Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316–1322.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Treatment trials. In: Mitsumoto H, Chad DA, Pioro EP, eds. Amyotrophic lateral sclerosis; contemporary neurology series. Philadelphia: FA Davis, 1998:329–359.
  28. ↵
    The ALS CNTF Treatment Study (ACTS) Group.Prognostic indicators of survival in amyotrophic lateral sclerosis. Neurology 1996;46:A208. Abstract.
    OpenUrl
  29. ↵
    Jeejeebhoy KN. Muscle function and nutrition. Gut 1986;27 (suppl 1):25–39.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise